Objective: How hexanucleotide (GGGGCC) repeat expansions in C9ORF72 cause amyotrophic lateral sclerosis (ALS) remains poorly understood. Both gain-and loss-of-function mechanisms have been proposed. Evidence supporting these mechanisms in vivo is, however, incomplete. Here we determined the effect of C9orf72 loss-of-function in mice. Methods: We generated and analyzed a conditional C9orf72 knockout mouse model. C9orf72 fl/fl mice were crossed with Nestin-Cre mice to selectively remove C9orf72 from neurons and glial cells. Immunohistochemistry was performed to study motor neurons and neuromuscular integrity, as well as several pathological hallmarks of ALS, such as gliosis and TDP-43 mislocalization. In addition, motor function and survival were assessed. Results: Neural-specific ablation of C9orf72 in conditional C9orf72 knockout mice resulted in significantly reduced body weight but did not induce motor neuron degeneration, defects in motor function, or altered survival. Interpretation: Our data suggest that C9orf72 loss-of-function, by itself, is insufficient to cause motor neuron disease. These results may have important implications for the development of therapeutic strategies for C9orf72-associated ALS.
a single intracerebroventricular injection of antisense oligonucleotides (ASOs) in mice does not affect motor function or anxiety. 14 To test the haploinsufficiency model and to determine whether lack of C9orf72 expression leads to motor neuron degeneration or abnormal motor function, we generated and analyzed a conditional C9orf72 knockout mouse model.
Materials and Methods
Mouse Husbandry, Breeding, and Genotyping
All animal use and care were in accordance with local institution guidelines. Mice were kept on a 12-hour light/dark cycle with food and water available ad libitum. B6;SJL-Tg(ACTFLPe)9205-Dym/J mice and B6.Cg-Tg(Nes-cre)1Kln/J mice were obtained from Jackson Laboratory (Bar Harbor, ME; 003800; 003771) and C57Bl/6J mice from Charles River Laboratories (Wilmington, MA). To generate C9orf72 loxP mice, a targeting construct was designed to insert an Frt-flanked neomycin cassette and 1 loxP site upstream of exon 4 and 1 loxP site downstream of exon 5 of C9orf72. Deletion of exons 4 and 5 targets all reported C9orf72 isoforms in the mouse. This construct was electroporated into C57Bl/6 embryonic stem cells. Correctly targeted stem cells, as determined by polymerase chain reaction (PCR) and Southern blot analysis, were injected into blastocysts, and chimeric mice were bred with C57Bl/6J mice. The resulting 
Antibody Generation
The anti-C9orf72 rabbit polyclonal antibody C9-2034 was generated from an N-terminal thioredoxin fusion of a stretch of 58 amino acids present in all human C9orf72 isoforms comprising MEDQGQSIIPMLTGEVIPVMELLSSMKSHSVPEEIDIADTVL NDDDIGDSCHEGFLLK. This was generated from a C9orf72 short isoform expression construct using the primers 5 0 -CCC GAATTCGAGAGAATGGAAGATCAGGGT-3 0 and 5 0 -GAAGC GGCCGCATCTGCTTCATCCAGCTTTTATGA-3 0 . The PCR product was digested and cloned into the EcoRI/NotI sites of pET32a (Clontech Laboratories, Mountain View, CA). Thioredoxin (Thx)-C9orf72-tail expression was induced in transformed BL21(DE3) Escherichia coli (Agilent Technologies, Santa Clara, CA) using 1mM Isopropyl b-D-1-thiogalactopyranoside (IPTG) for 3 hours at 378C. Thx-C9orf72-Short was purified using HisPur resin according to the manufacturer's instructions (Thermo Fisher Scientific, Waltham, MA) following solubilization in sonication buffer (20mM Tris pH 8.0, 100mM NaCl) using a VibraCell Ultrasonic Processor (Sonics & Materials, Newtown, CT). The anti-C9orf72 rabbit polyclonal antibody C9-2074 was generated by reimmunization of the previously described N-terminal thioredoxin fusion of full-length C9orf72 short isoform. 12 The respective purified fusion proteins were used as antigens for custom rabbit polyclonal antibody generation (Covalab, Villeurbanne, France). Custom antisera were immunoaffinity-purified against their antigen following preabsorption against Thx and glial fibrillary acidic protein (Thx-GFAP expressed in BL21[DE3] transformed with GFAP pET32a). Both antibodies detected a 50 to 55kDa protein in mouse and human brain lysates, as well as myc-tagged C9orf72 from transfected HEK293T cells. The anti-C9orf72 rabbit polyclonal antibodies were validated for Western blotting using siRNA-mediated knockdown of endogenous C9orf72 in HEK293T cells using 27-mer oligonucleotide duplexes as previously described. 12 Additional validation in SH-SY5Y neuroblastoma cells was performed following knockdown of endogenous C9orf72 using Dicer substrate RNAi interference using custom dicer substrate siRNA (DsiRNA; Integrated DNA Technologies, Coralville, IA). Custom DsiRNA oligonucleotide duplex sequences are C9ORF72-
FLuc-S1 exogenous reporter gene DsiRNA duplex was used as a nontargeting control. DsiRNA was transfected using the same conditions as 27mer oligonucleotide duplexes. Whole cell and tissue lysate preparation and Western blotting were performed as described previously. 12 Western blotting using the anti-C9orf72 rabbit polyclonal antibodies detected no C9orf72 expression in knockout mice (Fig 1) or reduced expression following knockdown of C9orf72 (in HEK293 or SHSY5Y cells; data not shown).
In Situ Hybridization
Fresh frozen mouse embryos, or spinal cord and brain tissue from adult mice were cut at 16 to 20mm on a cryostat. Nonradioactive in situ hybridization was performed as described previously. 15 A digoxigenin-labeled C9orf72 probe was transcribed from mouse cDNA (a 736bp fragment corresponding to nucleotides 298-1,034 of 3110043O21Rik) using a DIG RNA labeling SP6/T7 kit (Roche, Basel, Switzerland). Sense probes were used to confirm specificity. Images were taken on a Zeiss (Oberkochen, Germany) AxioSkop2 microscope.
Quantitative Real-Time PCR 
Western Blotting
Western blotting was performed as described previously. 16 In brief, fresh frozen tissue was homogenized in radioimmunoprecipitation assay buffer (50mM Tris pH 7.6, 150mM NaCl, 0.5mM ethylenediaminetetraacetic acid, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1% Triton-X-100, and protease inhibitor cocktail), centrifuged twice at 10,000 3 g, and the supernatant was used as total protein. 
Motor Function Testing
Mice were weighed and tested for their hindlimb extension reflex weekly. Every 3 weeks, mice performed 5 trials on an accelerating rotarod (Ugo Basile, Varese, Italy) at 4rpm with an acceleration of 0.2rpm/s for 180 seconds and the latency to fall was recorded. Mice that rotated passively were scored as fallen. Grip strength of front paws and of front and hind paws together was measured every 3 months using a grip strength meter (Bioseb, Vitrolles, France). Strength was measured 5 times for each mouse both for front and for front and hind paws. All behavioral tests were performed on 11 mice per genotype for each time point. Statistical analysis was carried out using R software (http://www.r-project.org). (Non-)linear mixed models were used to account for repeated measurements and other sources of correlation within the longitudinal data and to provide a correct model in case of missing data. For statistical analysis of body weight, a nonlinear mixed effects model was used with gender as a covariate. Interactions between time and behavioral tests were analyzed to study possible changes during follow-up. For rotarod and grip strength statistical analysis, a nonlinear mixed effects model was used with gender and body weight as covariates. Survival analysis was carried out using a Cox regression analysis with mean body weight as covariate.
Cox proportional hazard assumptions were tested.
Immunohistochemistry
Immunohistochemistry was performed as described previously. 17 Tissues were removed and cryoprotected in 30% sucrose after transcardial perfusion with 4% paraformaldehyde. Spinal cord and brain were cut at 20mm and mounted on SuperFrost Plus slides (Thermo Fisher Scientific City, IA), and anti-neurofilament (DSHB) antibodies. At least 150 neuromuscular junctions were counted per mouse. Images were taken on an Olympus (Tokyo, Japan) FluoView FV1000 confocal microscope or a Zeiss AxioScope microscope followed by image analysis using ImageJ. Statistical analysis was performed using Student t test (SPSS Statistics; IBM, Armonk, NY).
Results

Genetic Ablation of C9orf72 in Mice
Previous work analyzing C9orf72-LacZ knockin mice reported C9orf72 expression in neurons known to degenerate in ALS and FTD, such as cortical and spinal cord motor neurons. 18 To confirm and extend these findings, we performed in situ hybridization for the mouse C9orf72 orthologue, 3110043O21Rik (here referred to as C9orf72), at embryonic, postnatal, and adult stages. As reported previously, neuronal C9orf72 expression was detected in several regions of the adult brain and spinal cord (see Fig 1; Table) . 18 In contrast to previous work, however, prominent expression of C9orf72 was also observed in embryonic and early postnatal neurons. These included retinal ganglion cells, sensory neurons in the olfactory epithelium and in dorsal root ganglia, and spinal motor neurons. In addition, expression in nonneuronal tissues such as kidney and tooth was detected.
These results indicate that C9orf72 may also function during embryonic and postnatal development.
To circumvent problems such as embryonic lethality, we generated conditional C9orf72 knockout mice using the Cre-loxP system and bred the resulting 
Spinal cord C9orf72 fl/fl mice to Nestin-Cre mice (see Fig 1) . In
Nestin-Cre mice, Cre recombination occurs in neuronal and glial precursors from E10.5 onward. 19 The specific ablation of C9orf72 mRNA and protein in Nestin-Cre ;C9orf72 fl/fl mice, respectively. Note that only isoform 1 is detected at the protein level in mouse brain. b-Actin was used as a loading control. ***p < 0.001. L 5 loxP sites.
targeted in the C9orf72 conditional knockout mouse (Fig  2) . To confirm that the expression of all isoforms is affected by the excision of exons 4 and 5, we performed quantitative real-time PCR to detect expression of different exonic regions present in 1 or multiple isoforms. As expected, a reduction of C9orf72 mRNA levels was found for all exonic regions analyzed. In addition, we generated a new anti-C9orf72 antibody. This antibody was raised against a 58 amino acid stretch shared by all isoforms (C9-2034) . The other antibody used was reported previously and was raised using a large part of the C9orf72 protein. The region used is present in 2 of the 3 isoforms (C9-2074). 12 Western blotting using these antibodies showed a predicted 55kDa band, corresponding to isoform 1, that was lost in brain tissue of Nestin-Cre control littermates in viability, appearance, fertility, and the gross anatomical and histological appearance of the brain. Immunohistochemistry for ChAT, to visualize spinal motor neurons, did not reveal changes in neuron number or size (Fig 3A, B) . Furthermore, innervation of the gastrocnemius muscle by motor axons, as assessed by overlap between the pre-and postsynaptic compartment of the neuromuscular junction, was similar in Nestin-Cre
;C9orf72 fl/fl mice and controls (see Fig 3C, D) . Astro-and microgliosis are hallmarks of ALS. However, no differences in immunostaining for GFAP or Iba1, to label astrocytes or microglia, respectively, were detected between spinal cord or brain tissue from Nestin-Cre of defects in motor neuron number, size, and connectivity and no signs of gliosis or other pathological hallmarks of ALS (data not shown). Thus, C9orf72 deficiency in mice fails to cause several of the pathological hallmarks reported in ALS patients or mouse models.
A reduction in body weight was detected in all Nestin-Cre-positive mice, as has been previously reported for other studies using this Cre driver. 20 However, even when considering this effect, Nestin-Cre ;C9orf72 1/1 control mice (26.02%, p 5 0.019). This difference was detected at the first time point of measurements and did not significantly change in time (Fig 8) . To assess motor performance, the hindlimb extension reflex was tested (data not shown) and mice were assessed using an accelerating rotarod and a grip strength meter for a period of 18 months after birth. No differences in motor performance or grip strength were found between Nestin-Cre mice do not display overt defects in motor function or decreased survival.
Discussion
C9orf72 haploinsufficiency may contribute to the pathogenic mechanism in C9ALS/FTD patients. To test this hypothesis, we generated a conditional C9orf72 knockout mouse model. Two previous studies have reported the generation of C9orf72 knockout mice, but neither study provided a histological or behavioral characterization. 18, 21 In one of these studies, using C9orf72-LacZ knockin reporter mice, C9orf72 expression was not detected at embryonic and early postnatal stages in the mouse. 18 In contrast, we show neuronal C9orf72 expression at several sites in the embryonic nervous system, as well as in nonneuronal tissues. This observation is in line with a recent study showing expression of C9orf72 both inside and outside the nervous system of zebrafish embryos. 10 The cause of this apparent discrepancy is unknown but may include the inability of heterozygous LacZ reporter mice ANNALS of Neurology ;C9orf72 fl/fl mice. Our results are in apparent contrast with recent work in model organisms such as zebrafish and C. elegans. Knockdown or knockout, respectively, of C9orf72 orthologues in zebrafish and C. elegans causes motor deficits. These include agedependent motility defects and c-aminobutyric acidergic motor neuron degeneration in C. elegans, and motor axon and behavior deficits in zebrafish. 10, 13 The discrepancy with our results may be caused by the low homology of C9orf72 orthologues in humans and in zebrafish and C. elegans (76% and 23% compared to human C9ORF72, respectively) as compared to the high homology between human and mouse C9orf72 (98%). Another possible explanation could be redundancy of the C9orf72 gene in mammalian species. In line with our results, a single treatment of wild-type mice with ASOs directed against C9orf72 did not lead to motor abnormalities. 14 Together, our data suggest that loss of C9orf72 on its own is insufficient to cause ALS. Our results, however, do not rule out the possibility that C9ORF72 loss-of-function modulates the disease process and influences disease onset, severity, and duration in C9ALS/FTD patients. The disease mechanisms caused by repeat expansions in C9ORF72 are likely to be complex and may ultimately result from interplay between C9ORF72 loss-and gain-offunction mechanisms. 23, 24 In support of a gain-of-function mechanism, recent work shows that AAV-mediated expression of 66 GGGGCC repeats in the adult mouse brain induces key features of ALS/FTD, such as TDP-43 pathology and behavioral deficits. 6 A different study, using transgenic mice with inducible expression of hexanucleotide (GGGGCC) repeats, found ubiquitinated inclusions, but these inclusions were not detected in neuronal populations relevant for ALS/FTD and no motor phenotype was found. 25 Our finding that loss of C9orf72 function does not lead to motor neuron disease in mice has consequences for therapeutic strategies, because it indicates that ASOs directed at the repeat expansion that also lower C9ORF72 expression are unlikely to have negative side effects due to reduced C9ORF72 expression. ;C9orf72 fl/fl mice is similar to control mice.
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